Tiger Brokers

Voyager Technologies Wins Contract for ISS Biopolymer Cancer Implant Study

MT Newswires Live
Oct 06

Voyager Technologies (VOYG) has secured a contract from the Center for the Advancement of Science in Space to manage Symphony Biosciences' biopolymer cancer implant experiment aboard the International Space Station, the company said Tuesday.

Financial details weren't disclosed.

Under the contract, Voyager is expected to adapt the experiment hardware for station equipment, support NASA safety reviews, manage launch integration and on-orbit operations, and help test SymphNode, a device designed to restore immune response by recruiting and activating T cells to fight cancer.

Voyager will return the experiment samples and data after the study and provide post-flight and close-out reporting.

Price: 30.93, Change: +0.73, Percent Change: +2.41

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10